同步放化疗方案（NSCL-F）

同步放化疗方案 [a]

首选（非鳞癌）

•卡铂AUC 5，第1天；培美曲塞500mg/m²，第1天；每21天为1个周期，共4个周期；同步胸部放疗 [1] ,  , [c] , [d] , [e]

•顺铂75mg/m²，第1天；培美曲塞500mg/m²，第 1 天；每21天为1个周期，共3个周期；同步胸部放疗 [2] , [3] ,  , [c] , [d] , [e] , [f]

•卡铂AUC 2；紫杉醇45-50mg/m²，每周1次；同步胸部放疗 [4] ,  , [c] , [d] , [e] , [g]

•顺铂50mg/m²，第1、8、29、36天；依托泊苷50mg/m²，第1-5天和第29-33天；同步胸部放疗 [5] , [6] ,  , [c] , [d] , [e]

首选（鳞癌）

•卡铂AUC 2；紫杉醇45-50mg/m²，每周1次；同步胸部放疗 [6] ,  , [c] , [d] , [e] , [g]

•顺铂50mg/m²，第1、8、29 、36天；依托泊苷50mg/m²，第 1-5 天和第29-33天；同步胸部放疗 [5] , [6] ,  , [c] , [d] , [e]

不可切除II/III期、PS 0-1、根治性同步放化疗后无疾病进展NSCLC患者的巩固治疗

•度伐利尤单抗10mg/kg，静脉注射，每2周一次，或1500mg，每4周一次，最长持续12个月（适用于体重≥30kg的患者） [7] , [8] , [h] [ i ], （对III期患者为1类证据，对II期患者为2A类证据）（EGFR 19号外显子缺失或L858R突变阳性肿瘤除外）

•奥希替尼80mg，每日一次，持续用药直至疾病进展（若存在EGFR 19号外显子缺失或L858R突变）（对III期患者为1类证据，对II期患者为2A类证据） [9] ,

---

a For patients with superior sulcus tumors, the recommendation is for 2 cycles concurrent with RT and 2 more cycles after surgery. Rusch VW, Giroux DJ, Kraut MJ,

et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416

(Intergroup Trial 0160). J Clin Oncol 2007;25:313-318.

b Regimens can be used as preoperative/adjuvant chemotherapy/RT.

c Regimens can be used as definitive concurrent chemotherapy/RT.

d For eligible patients, durvalumab may be used after noted concurrent chemotherapy/RT regimens.

e For eligible patients, osimertinib may be used after noted concurrent chemotherapy/RT regimens in patients with EGFR exon 19 deletion or L858R mutation.

f If using durvalumab or osimertinib, additional chemotherapy after radiation is not recommended. If not using durvalumab or osimertinib, an additional 4 cycles of

pemetrexed 500 mg/m² may be used.

g If using durvalumab or osimertinib, additional chemotherapy after radiation is not recommended. If not using durvalumab or osimertinib, an additional 2 cycles every 21

days of paclitaxel 200 mg/m² and carboplatin AUC 6 may be used.

h In patients with tumors that are positive for EGFR exon 19 deletion or L858R mutation there is risk of toxicity when TKI is administered in temporal proximity to

immunotherapy.

i For patients who have received sequential chemoradiation, durvalumab can be considered as consolidation immunotherapy or, if EGFR exon 19 deletion or L858R

mutation, osimertinib is recommended.

---

来源：NCCN：非小细胞肺癌（Non-Small Cell Lung Cancer）   NCCN-NSCLC-2026V6